2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-147401A
    Sitagliptin fenilalanil hydrochloride 1339954-75-4 98.94%
    Sitagliptin fenilalanil hydrochloride is a dipeptidyl aminopeptidase 4 (DPP-4) inhibitor.
    Sitagliptin fenilalanil hydrochloride
  • HY-B0166GL
    L-Ascorbic acid (GMP Like) 50-81-7 99.88%
    L-Ascorbic acid (GMP Like) is the GMP Like class L-Ascorbic acid (HY-B0166). L-Ascorbic acid (L-Ascorbate, Vitamin C), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells.
    L-Ascorbic acid (GMP Like)
  • HY-W015608R
    2-Phenylpropionic acid (Standard) 492-37-5 98.18%
    2-Phenylpropionic acid (Standard) is the analytical standard of 2-Phenylpropionic acid (HY-W015608). This product is intended for research and analytical applications. 2-Phenylpropionic acid is an intermediate in the metabolism of alpha-Methylstyrene. 2-Phenylpropionic acid covalently binds to rat liver protein. 2-Phenylpropionic acid can be used in the research of nonsteroidal anti-inflammatory agents.
    2-Phenylpropionic acid (Standard)
  • HY-W009216S1
    2'-Deoxycytidine-5'-monophosphate-13C9,15N3 dilithium 99.8%
    2'-Deoxycytidine-5'-monophosphoric acid-13C9,15N3 dilithium is 13C and 15N-labeled 2'-Deoxycytidine-5'-monophosphoric acid (HY-W009216). 2'-Deoxycytidine-5'-monophosphoric acid is an endogenous metabolite.
    2'-Deoxycytidine-5'-monophosphate-13C9,15N3 dilithium
  • HY-B0258S
    Gemfibrozil-d6 1184986-45-5 98.71%
    Gemfibrozil-d6 is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.
    Gemfibrozil-d6
  • HY-B1278S1
    α-Tocopherol-d6 acetate 143731-16-2 99.67%
    α-Tocopherol-d6 (acetate) is the deuterium labeled D-α-Tocopherol acetate. D-α-Tocopherol acetate (D-Vitamin E acetate) can be hydrolyzed to d-alpha-tocopherol (VE) and absorbed in the small intestine.
    α-Tocopherol-d6 acetate
  • HY-A0023AS1
    Alogliptin-d3 1133421-35-8 99.61%
    Alogliptin-d3 is the deuterium labeled Alogliptin. Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of DPP-4 with an IC50 of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin can be used for the research of type 2 diabetes.
    Alogliptin-d3
  • HY-10061
    Lesogaberan 344413-67-8 98%
    Lesogaberan (AZD-3355) is a potent and selective GABAB receptor agonist with an EC50 of 8.6 nM for human recombinant GABAB receptors. The affinity (Kis) of Lesogaberan for rat GABAB and GABAA receptors, as measured by displacement of [3H]GABA binding in brain membranes: 5.1 nM and 1.4 μM, respectively. Lesogaberan inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action.
    Lesogaberan
  • HY-10250
    Triciribine phosphate 61966-08-3 ≥99.0%
    Triciribine phosphate (TCN-P) inhibits amidophosphoribosyltransferase by an allosteric mechanism which affects the first committed step of de novo purine biosynthesis. Triciribine phosphate also inhibits  IMP dehydrogenase which is the first committed step of guanosine nucleotide synthesis. Tricilibine phosphate does not affect ligase activity.
    Triciribine phosphate
  • HY-10383
    J-104132 198279-45-7 98%
    J-104132 (L-753037) is a potent, orally active, selective and competitive ETA/ETB receptor antagonist with Ki of 0.034 nM for ETA and 0.104 nM for ETB receptors. J-104132 inhibits Endothelin-1 (ET-1) (HY-P71446)-induced signaling and vascular contractions in vitro. J-104132 alleviates hypertension, vascular remodeling, and diabetic endothelial dysfunction in vivo by dual ETA/ETB blockade. J-104132 can be used for research on diabetic vascular complications[1][3].
    J-104132
  • HY-10397
    EP1013 223568-55-6
    EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetes.
    EP1013
  • HY-10825
    DG051 929915-58-2 99.86%
    DG051 is a potent leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis in the enzyme assay with an IC50=47 nM.
    DG051
  • HY-10957
    L-692429 145455-23-8 99.90%
    L-692429 (MK-0751) is a benzolactam derivative and a nonpeptidyl growth hormone secretagogue (GHS) agonist. L-692429 binds to G protein-coupled receptor with a Ki of 63 nM.
    L-692429
  • HY-11030
    SNT-207858 1104080-42-3 98%
    SNT207858 is a selective, blood brain barrier penetrating, potent and orally active melanocortin-4 (MC-4) receptor antagonist. SNT207858 has an IC50 of 22 nM (binding) and 11 nM (function) on the MC-4 receptor.
    SNT-207858
  • HY-12433
    BMS-819881 1197420-05-5 99.78%
    BMS-819881 is a melaninconcentrating hormone receptor 1 (MCHR1) antagonist, which binds rat MCHR1 with a Ki of 7 nM. BMS-819881 also is selective and potent for CYP3A4 activity with an EC50 of 13 μM.
    BMS-819881
  • HY-12611
    Sergliflozin etabonate 408504-26-7 99.64%
    Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes.
    Sergliflozin etabonate
  • HY-12614
    AMG-1694 1361217-07-3 98%
    AMG-1694 is a potent glucokinase–glucokinase regulatory protein (GK-GKRP) disruptors and promotes the dissociation of the GK-GKRP complex with an IC50 of 7 nM, indirectly increasing GK enzymatic activity. AMG-1694 potently reverses the inhibitory effect of GKRP on GK activity and promotes GK translocation. AMG-1694 normalizes blood glucose levels in several rodent models of diabetes and lowes blood glucose restricted to diabetic and not normoglycaemic animals.
    AMG-1694
  • HY-12647
    GPR40 Activator 2 1312787-30-6 99.63%
    GPR40 Activator 2 is a potent GPR40 activator from patents WO 2012147516 A1, WO 2012046869A1 and WO 2011078371 A1.
    GPR40 Activator 2
  • HY-12738
    PF-3882845 1023650-66-9 99.90%
    PF-3882845 is a remarkably high affinity selective and orally efficacious mineralocorticoid receptor (MR binding IC50=2.7 nM) antagonist for hypertension and nephropathy. PF-3882845 also binds to progesterone receptor (PR) with the binding IC50 of 310 nM.
    PF-3882845
  • HY-13504
    PIK-293 900185-01-5 99.41%
    PIK-293, an analog of IC87114, is a PI3K inhibitor, with IC50 values of 0.24 μM, 10 μM, 25 μM and 100 μM for p110δ, p110β, p110γ and p110α, respectively.
    PIK-293
Cat. No. Product Name / Synonyms Application Reactivity